Brief: AB Science Announces Promising Results Of Phase 3 Study Of Alzheimer-Treating Drug
29/07/2021 18:20
July 29 (Reuters) - AB Science SA ABS.PA :
* ANNOUNCED THAT RESULTS FROM ITS PHASE 3 AB09004 STUDY ON
MILD TO
MODERATE ALZHEIMER’S DISEASE HAVE BEEN PRESENTED AT THE AAIC
* MASITINIB ADMINISTERED AT 4.5 MG/KG/DAY,SIGNIFICANTLY
SLOWED
COGNITIVE DETERIORATION RELATIVE TO PLACEBO
* DATA SHOWED REDUCED LOSS OF FUNCTIONAL ABILITY IN
ACTIVITIES OF
DAILY LIVING
Source text for Eikon: ID:nGNE8CntPP
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease